Cormedix Inc (CRMD)
5.45
+0.04
(+0.83%)
USD |
NASDAQ |
Apr 17, 16:00
5.45
0.00 (0.00%)
After-Hours: 19:26
Cormedix Cash from Financing (TTM): 55.92M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 55.92M |
September 30, 2023 | 61.49M |
June 30, 2023 | 19.03M |
March 31, 2023 | 22.09M |
December 31, 2022 | 17.90M |
September 30, 2022 | 11.85M |
June 30, 2022 | 11.42M |
March 31, 2022 | 3.181M |
December 31, 2021 | 41.76M |
September 30, 2021 | 57.08M |
June 30, 2021 | 79.02M |
March 31, 2021 | 78.85M |
December 31, 2020 | 40.10M |
September 30, 2020 | 24.57M |
June 30, 2020 | 12.66M |
March 31, 2020 | 12.67M |
December 31, 2019 | 25.80M |
September 30, 2019 | 44.39M |
June 30, 2019 | 41.23M |
March 31, 2019 | 42.10M |
December 31, 2018 | 29.40M |
September 30, 2018 | 18.39M |
June 30, 2018 | 11.52M |
March 31, 2018 | 23.44M |
December 31, 2017 | 20.52M |
Date | Value |
---|---|
September 30, 2017 | 13.17M |
June 30, 2017 | 17.82M |
March 31, 2017 | 7.181M |
December 31, 2016 | 7.092M |
September 30, 2016 | 8.277M |
June 30, 2016 | 6.929M |
March 31, 2016 | 37.07M |
December 31, 2015 | 43.63M |
September 30, 2015 | 42.43M |
June 30, 2015 | 39.23M |
March 31, 2015 | 6.932M |
December 31, 2014 | 8.358M |
September 30, 2014 | 11.21M |
June 30, 2014 | 12.96M |
March 31, 2014 | 12.98M |
December 31, 2013 | 5.204M |
September 30, 2013 | 2.714M |
June 30, 2013 | 1.641M |
March 31, 2013 | 1.601M |
December 31, 2012 | 1.126M |
September 30, 2012 | 0.755M |
June 30, 2012 | -0.015M |
March 31, 2012 | 0.00 |
December 31, 2011 | 0.00 |
September 30, 2011 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
3.181M
Minimum
Mar 2022
79.02M
Maximum
Jun 2021
34.79M
Average
25.80M
Median
Dec 2019
Cash from Financing (TTM) Benchmarks
BioXcel Therapeutics Inc | 26.52M |
Assertio Holdings Inc | -44.20M |
Verastem Inc | 134.19M |
Ocular Therapeutix Inc | 169.83M |
PAVmed Inc | 31.17M |